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1. Introduction 
This chapter aims to draw attention to the features that distinguish drug-induced vasculitis 
from those of idiopathic autoimmune syndromes, first and foremost primary vasculitides.  
Development of a systemic drug-induced syndrome only develops in a minority of patients 
treated with a drug over a prolonged period of time, whereas cutaneous vasculitis occurs quite 
commonly. The most frequent symptoms as onset are arthralgia, myalgia and skin rash. Early 
withdrawal of the offending drug mostly leads to complete recovery while more advanced 
disease and late withdrawal of the drug may necessitate use of corticosteroid and/or 
immunosuppressive therapy. The recent discovery of anti-neutrophil cytoplasm antibodies 
(ANCA) in a large serological subset of drug-induced vasculitis caused by long-term 
antithyroid drug treatment has opened new avenues for differential diagnostics. Certain 
medications such as propylthiouracil can induce ANCA associated vasculitis. This chapter 
focuses on the data on causal drugs, possible pathogenesis, clinical description, diagnosis, 
treatment and prognosis of patients with drug-induced vasculitis. ANCA with specificity to 
more than one lysosomal antigen combined with presence of antibodies to histones and beta-2 
glycoprotein 1 constitute a unique serological profile for drug-induced vasculitis. 
The pathogenesis of drug-induced ANCA associated vasculitis might be multifactorial. The 
clinical manifestations are similar to those of primary ANCA associated vasculitis, but 
ANCA with multi-antigenicity may help to differentiate it from primary ANCA associated 
vasculitis. Rational use of laboratory marker profiles is likely to aid in distinguishing drug-
induced from idiopathic syndromes. However, the use of ANCA and other autoantibodies 
as biomarkers of different phenotypes of drug-induced vasculitis is one of the focuses of this 
chapter. 
To date, ANCA are important serological markers for certain small-vessel vasculitides, 
encompassing Wegener granulomatosis (WG), microscopic polyangiitis (MPA) and Churg–
Strauss syndrome (CSS). By indirect immunofluorescence (IIF) technique, ANCAs are 
classified as a perinuclear pattern (P-ANCA) and a cytoplasmic pattern (C-ANCA). C-ANCA 
is caused almost exclusively by antibodies against proteinase 3 (PR3). In contrast, P-ANCA can 
be caused by antibodies reacting with a variety of different neutrophil granule constituents, 
including myeloperoxidase (MPO), lactoferrin, human leucocyte elastase (HLE) and others. 
Evidence is mounting that these specific antibodies are pathogenic in small-vessel vasculitis. 
However, the aetiology of ANCA associated vasculitis is largely unknown. 
The diagnosis of drug-induced ANCA associated vasculitis is based on the temporal 
relationship between clinically evident vasculitis and administration of the offending drugs, 
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and excluding medical conditions that mimic vasculitis and other definable types of 
vasculitis. After the diagnosis of drug-induced ANCA associated vasculitis was made, the 
offending drugs should be withdrawn immediately, and appropriate immunosuppressive 
therapy should be administered only for patients with vital organ involvement. The 
duration of immunosuppressive therapy should be much shorter than that in primary 
ANCA associated vasculitis and long-term maintenance therapy might not be necessary. 
The prognosis of patients with drug-induced ANCA associated vasculitis is good as long as 
the offending drug is discontinued in time. 
This chapter summarizes the causal drugs, possible pathogenesis, clinical description, 
diagnosis, treatment and prognosis of drug-induced ANCA associated vasculitis. 
2. Drug-induced vasculitis  
Drug-induced vasculitis usually attacks the skin and sometimes the subcutaneous part of 
the skin, but sometimes also the kidneys and the lungs. Clinical symptoms include 
arthralgias and myalgias but usually do not develop into overt arthritis or myositis, 
manifested as muscle weakness. End-stage kidney disease due to glomerular vasculitis may 
occur, but early removal of the offending drug most often leads to resolution of the 
glomerular inflammation. A few cases of drug-induced vasculitis presenting with a 
hemorrhagic syndrome due to lung capillaritis have been reported. Drug-induced vasculitis 
patients typically harbor ANCA directed to one or more neutrophil cytoplasm antigens, the 
most common antigens being the granule proteins MPO, HLE, cathepsin G, and lactoferrin. 
In one study from Boston (Choi, 2000), the levels of MPO-ANCA were found to be much 
higher in 30 patients with drug-induced MPO-ANCA vasculitis than those usually found in 
idiopathic vasculitides, and there was a strong association between presence of HLE-ANCA 
and lactoferrin-ANCA and exposure to the candidate drugs. A study from Denmark 
showed a strong association between heredity and development of drug-induced vasculitis 
during treatment with propylthiouracil in monozygotic triplets with Graves’ disease. Two of 
these children that were treated with propylthiouracil got multispecific ANCA including 
HLE-ANCA, while the third triplet had no signs of drug-induced vasculitis and no ANCA 
during treatment with carbimazole. 
To date, many studies have indicated that drug-induced vasculitis may be a complication of 
therapy with prior use of certain medications in some patients, and unreported and/or 
undiagnosed cases may be beyond our imagination. As shown in Table 1, the most often 
implicated drug in the published work is propylthiouracil, which may result from more 
frequent prescriptions in clinical practice. Clear evidence for an association with the 
development of drug-induced vasculitis has also been shown for the following drugs: 
hydralazine, anti-tumour necrosis factor-α (TNF-α) agents, sulfasalazine, D-penicillamine 
and minocycline, however, most of them were limited to case reports. Propylthiouracil is a 
common anti-thyroid drug widely used all over the world. In the published work, over a 
hundred cases of propylthiouracil-induced vasculitis have been reported. Further studies in 
pathogenesis, treatment and long-term outcomes of patients with propylthiouracil induced 
vasculitis provide useful information on understanding drug-induced vasculitis. It has been 
shown that propylthiouracil is implicated in 80–90% cases of vasculitis induced by anti-
thyroid drugs, while cases related to others are less frequent such as methimazole, 
carbimazole and benzylthiouracil. The increasing use of so-called ‘biologic’ agents in 
medical practice has been accompanied by growing evidence on the toxicity profile of these 
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agents, including drug-induced vasculitis. Anti-TNF-α drugs, such as adalimumab, 
infliximab and etanercept, are now established therapy in the management of rheumatoid 
arthritis and several other chronic inflammatory diseases. Repeated treatment with these 
agents can lead to the development of autoantibodies, including antinuclear antibodies 
(ANA), anti-dsDNA and anti-cardiolipin antibodies, in up to 10% of patients. The 
autoantibody synthesis is associated with a greater cumulative dose of therapy. Although 
uncommon, some patients receiving anti-TNF-α agents were found to develop vasculitis. 
Minocycline, a semi-synthetic lipophilic tetracycline, is the favoured antibiotic for the 
treatment of acne and rheumatic diseases. The use of minocycline over the past decade has 
led to numerous reports on drug-induced lupus. Interestingly, the laboratory features of 
minocycline-induced lupus include positive ANA and frequently positive p-ANCA (>67% 
of cases). In Marzo-Ortega’s study, 7% of the minocycline-treated patients at some point in 
the past became ANCA positive, however, only a few cases indicated the occurrence of 
drug-induced vasculitis. Because there seems to be a wide serological overlap between 
drug-induced lupus and drug-induced vasculitis, it may be difficult to discriminate between 
the two categories. Also, it might raise suspicion that some patients may actually contract 
drug-induced vasculitis rather than drug-induced lupus. In addition, there are a few 
published reports indicating the association between treatment with other drugs and the 
occurrence of vasculitis, including allopurinol, cephotaxime, clozapine, levamisole, 
phenytoin and thioridazine. However, the causative relationship is much less certain. 
Leukotriene antagonists (LTA, such as montelukast and zafirlukast) have been implicated in 
the pathogenesis of CSS. Further studies showed that no significant association was 
observed between CSS and LTA after controlling for the use of other anti-asthma drugs.  In 
a case-crossover study, it was suggested that the onset of CSS might be not associated with 
montelukast but a phenomenon possibly associated with a group of medications prescribed 
for long term control of severe asthma. Based on this evidence, the National Institutes of 
Health/US Food and Drug Administration panel concluded that no one class of LTA was 
associated with CSS and that LTA are safe.  A possible clue to distinguish the patients with 
early CSS from those with idiopathic asthma is that the former patients tend to have severe 
upper airway disease, especially sinusitis, with radiographs showing paranasal 
abnormalities. 
2.1 Epidemiology 
There are no clear data on the prevalence of drug-induced vasculitis due to lack of 
prospective studies. Several cross-sectional studies reported that the prevalence of 
propylthiouracil induced vasculitis ranged from 20% to 64%. In some other study (Gao, 
2004), ANCA was detected in 22.6% of patients treated with propylthiouracil, but only 6.5% 
patients had clinical evidence of drug-induced vasculitis. In Slot’s study (Slot, 2005); ANCA 
and drug-induced vasculitis were present in 11% and 4% of patients treated with anti-
thyroid drugs, respectively. However, in Choi’s study (Choi, 2000), no patient in any of the 
active study drug groups (minocycline, for a 48-week trial; sulfasalazine, for a 37-week trial; 
penicillamine, for a 104- week trial) demonstrated ANCA seroconversion. Some researchers 
speculated that it might be due to a short observation period, and the prevalence of positive 
ANCA might be higher in patients with much long-standing therapy. Prospective, 
longitudinal studies with a larger cohort of patients are needed to establish the true 
prevalence of drug-induced vasculitis. 
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2.2 Pathogenesis 
A variety of agents may produce a typical clinical picture together with a similar 
autoimmune profile, suggesting a common mechanism for drug-induced vasculitis. To date, 
the mechanism is far from fully understood and it might be multifactorial. 
 Most drugs are low-molecular-weight substances, and require the formation of a 
complex to stimulate antibody formation and then to drive an immune response. One 
hypothesis (Jiang, 1994)  proposed that activated neutrophils in the presence of 
hydrogen peroxidase released MPO from their granules, which converted the offending 
drugs such as prophythiouracil and hydralazine into cytotoxic products, then the drugs 
and their metabolites were immunogenic for T cells, which in turn activated B cells to 
produce ANCA. 
 The offending drugs and their metabolites may accumulate within neutrophils, bind to 
MPO and modify its configuration, with subsequent intermolecular determinant 
spreading the autoimmune response to other autoantigens and turning neutrophil 
proteins (including elastase, lactoferrin and nuclear antigens) immunogenic. 
 Some drugs like sulfasalazine could induce neutrophil apoptosis. Moreover, neutrophil 
apoptosis, in the absence of priming, is associated with translocation of ANCA antigens 
to the cell surface, which then induce the production of ANCA, and ANCA in turn is 
able to bind the membrane-bound antigens, causing a self-perpetuating constitutive 
activation by cross-linking PR3 or MPO and Fcγ receptors.  
The oxidation activity of MPO could be inhibited by prophythiouracil and prophythiouracil 
-induced MPO-ANCA in a dose-dependent manner, which might also be involved in the 
pathogenesis of drug-induced vasculitis. The cytotoxic products of the offending drug, 
ANCA as well as cytotoxic neutral serine proteinases, degranulated from the activated 
neutrophils, could directly cause vascular damage. In other cases, the causal drugs (e.g. anti-
TNF-α agents) may act as modulators of the normal immune system, rendering it 
permissive for self-directed responses.  Rheumatoid arthritis is generally considered as a T-
helper cell (Th) 1-mediated disease and TNF-α plays an important role in driving Th1-
associated responses. Other forms of autoimmunity, for example, systemic lupus 
erythematosus and vasculitis (especially CSS and MPA), are characterized by a Th2 cytokine 
profile with prominent B-cell activation. Therefore, anti-TNF-α agents, administered in 
patients with rheumatoid arthritis, may shift the immune system from a Th1 to a Th2 profile 
thus upregulating antibody production. Alternatively, an increase in clinical or subclinical 
bacterial infections in the setting of TNF-α blockade might act as an immunostimulant and 
enable autoantibody production by inducing polyclonal B-cell activation. It is also 
speculated that drug-induced vasculitis might be genetic factors linked, because four out of 
six patients with minocycline-induced P-ANCA had human leucocyte antigen (HLA) 
DRB1*1104. The major histocompatibility complex (MHC) class II background may indicate 
that autoantibody production in these patients is driven by a genetically restricted T-cell 
response to epitopes from native or drug-modified MPO. Indeed, the ability of exogenous 
agents to induce vasculitis may be an opportunity, as a greater understanding of drug 
induced vasculitis is likely to provide insight into the nature of primary autoimmunity. 
Several studies have demonstrated that the majority of patients with drug-induced ANCA 
were free from clinically evident vasculitis. These conditions provide a natural platform for 
the study of idiopathic autoimmune disease. The autoantibody response is pathogenic will 
depend on many factors including the characteristics of the autoantibodies such as epitope 
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specificity, avidity, subclass and idiotype. A series of studies on prophythiouracil-induced 
vasculitis has demonstrated the following. 
 
Antibiotics 
 
Cephotaxime 
Minocycline 
Anti-thyroid drugs 
Benzylthiouracil 
Carbimazole 
Methimazole 
Prophythiouracil 
 
Anti-tumor necrosis factor-α agents 
 
Adalimumab 
Etanercept 
Infliximab 
 
Psychoactive agents 
 
Clozapine 
Thioridazine 
 
Miscellaneous drugs 
 
Allopurinol 
D-Penicillamine 
Hydralazine 
Levamisole 
Phenytoin 
Sulfasalazine 
Table 1. Medications associated with drug-induced vasculitis 
 Almost all the patients with overt clinical vasculitis had MPO-ANCA or PR3-ANCA, 
which indicated that anti-MPO and anti-PR3 antibodies, just like those in primary 
ANCA associated vasculitis, might also be associated with the occurrence of clinically 
active vasculitis induced by drugs. 
 A higher MPO-ANCA level, over a threshold, might be necessary to induce clinically 
evident vasculitis. 
 Patients with prophythiouracil-induced vasculitis tended to have higher titres and 
higher avidity of MPO-ANCA than those with prophythiouracil induced anti-MPO 
antibodies but without clinical vasculitis. 
 Most patients with prophythiouracil-induced ANCA but without clinical vasculitis had 
polyclonal MPO-ANCA recognizing both linear and conformational epitopes of the 
heavy chain of MPO; however, some patients with nephritis had MPO-ANCA 
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recognizing only the linear sites. They supposed that this clonality of MPO-ANCA 
might be a risk factor to induce clinical vasculitis. 
 Anti-endothelial cell antibodies (AECA) are implicated in the pathogenesis of vascular 
injury. It was found that the majority (10/11) of patients with active prophythiouracil-
induced vasculitis had serum AECA and their serum AECA disappeared quickly in 
remission; more importantly, patients with prophythiouracil induced ANCA but 
without clinical vasculitis did not have AECA. These findings indicated that AECA 
indeed might play an important role in the pathogenesis of drug-induced vasculitis. 
The studies on immunological characteristics of drug induced ANCA might provide useful 
information on the pathogenetic role of ANCA in primary vasculitis. Some studies have 
shown that although serum ANCA in patients with primary ANCA associated vasculitis 
usually recognized only one target antigen, either MPO or PR3, antibodies against multiple 
ANCA antigens, especially the antigens other than MPO and PR3, might be the 
characteristic of drug-induced ANCA. Compared with immunological characteristics of 
anti-MPO antibodies in sera from patients with primary ANCA associated vasculitis, 
prophythiouracil-induced anti-MPO antibodies usually had a higher titre but lower avidity. 
MPO-ANCA from patients with prophythiouracil-induced ANCA associated vasculitis 
might recognize more restricted epitopes of MPO, although the epitopes were overlapping 
between the two groups. In a study of ANCA immunoglobulin (Ig)G subclass distribution, 
the anti-MPO IgG3 subclass, which has a potent complement-activation capacity and a 
firmly binding ability to Fc receptors on mononuclear cells, was not detectable in sera from 
patients with prophythiouracil-induced vasculitis. Furthermore, the levels of IgG4 subclass 
of MPO-ANCA decreased dramatically after cessation of prophythiouracil, in contrast to 
primary ANCA associated vasculitis, and this indicated that the production of 
prophythiouracil-induced MPO-ANCA might be a result of chronic antigen 
(prophythiouracil) stimulation. The above studies provide substantial evidence that the 
mechanisms of ANCA production might be different between prophythiouracil-induced 
vasculitis and primary ANCA associated vasculitis. 
2.3 Clinical manifestations 
The clinical manifestations of drug-induced vasculitis are similar to those of primary 
vasculitides, which range from less specific syndromes (fever, malaise, arthralgia, myalgia, 
weight loss) to single tissue or organ involvement and life-threatening vasculitis. Some 
researchers suggested that more severe specific organ involvement might develop in 
patients with non-specific systemic syndrome when the casual drug was not withdrawn in 
time. The clinical characteristics of drug-induced vasculitis are more likely in the category of 
MPA and isolated glomerulonephritis (GN) in the published work. Kidney is the most 
common involved organ and the renal features vary widely, including haematuria, 
proteinuria and elevated serum creatinine. Intra-alveolar hemorrhage is the most commonly 
reported pulmonary manifestation with consequent cough, dyspnea and haemoptysis. Some 
patients may only have lung involvement such as acute respiratory distress syndrome and 
interstitial pneumonia and without renal injury. Contrary to idiopathic vasculitides, drug-
induced vasculitis usually has a milder course, and fewer patients have rapidly progressive 
GN in drug-induced vasculitis. Rare clinical manifestations were also described in case 
reports such as sensorineural hearing loss, pericarditis, pyoderma gangrenosum,  
central nervous system vasculitis presenting as cognitive symptoms and cerebral 
pachyleptomeningitis. 
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2.4 Laboratory and histopathology findings 
There is no unique clinically pathological or laboratory marker for discrimination between 
drug-induced vasculitis and other vasculitides. The laboratory abnormalities could indicate 
organ involvement. Anemia is common in patients with drug-induced vasculitis. Urine 
abnormalities have consisted of haematuria and proteinuria in patients with kidney 
vasculitis. Accurate assessment of disease activity within the lungs may be difficult because 
disease activity correlates poorly with pulmonary symptoms. A plain chest radiograph is a 
tool to monitor disease activity and high-resolution computed tomography (CT) scanning of 
the chest offers a more sensitive imaging technique. Although acute-phase reactants such as 
erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) are usually elevated in 
patients with drug-induced vasculitis on diagnosis, they are neither sufficiently sensitive 
nor specific in making the diagnosis. In some studies, ESR, which was associated with the 
Birmingham Vasculitis Activity Score, might be a better indicator for disease activity than 
the titres of ANCA. Laboratory markers, including selected autoimmune serological 
findings such as ANA, anti-dsDNA and rheumatoid factor among others are commonly 
used for excluding other diseases or diagnosing other types of vasculitides. 
Because detection of ANCA might serve as a warning of the possibility of drug-induced 
vasculits, ANCA assays using combined IIF and antigen-specific enzyme-linked 
immunosorbent assays (ELISA) rather than relying on either test alone are recommended 
in all patients suspected of drug-induced vasculitis. Detection of IgG ANCA is a routine 
laboratory test, and the presence of high titre IgM MPO-ANCA has also been noted in 
some cases. Eighty to ninety percent of cases are positive for P-ANCA, and almost all the 
patients with drug-induced vasculitis had antibodies to MPO rather than PR3. It has been 
shown that autoantibodies against multiple ANCA antigens might be the characteristic of 
drug-induced ANCA. Merely ANCA directed to other specific target antigens such as 
lactoferrin and HLE among others (except MPO and PR3), were found in rare cases. 
ANCA was also detected in bronchoalveolar lavage fluid (BALF) from a patient with 
drug-induced interstitial pneumonia. Although ANCA is an important serological marker 
for certain small-vessel vasculitides, it might not be suitable for monitoring the disease 
activity of drug-induced vasculitis. After discontinuation of the offending drug, even after 
immunosuppressive therapy, serum ANCA may still remain positive in remission in the 
majority of patients with drug-induced vasculitis for up to 5 years, and an increasing of 
ANCA titres may also occur without overt clinical relapse. Some studies showed that 
although the levels of MPO-ANCA decreased slowly, other immunological characteristics 
of MPO-ANCA might change substantially. For example, the avidity of MPO-ANCA 
could decrease rapidly after withdrawal of medication, indicating that the avidity of anti-
MPO antibodies might be a more sensitive serological biomarker to monitor disease 
activity. 
Tissue biopsy is usually necessary to provide a definitive diagnosis of vasculitis and to 
exclude other diseases. Specimens may come from skin lesions, renal and lung biopsies. 
Skin lesions are characterized by leucocytoclasia and fibrinoid necrosis of the blood vessels. 
The renal biopsy is recommended in patients with kidney vasculitis in order to reveal the 
disease severity and to guide treatment. Typical pauci-immune necrotizing crescentic GN 
could be identified in patients with drug-induced vasculitis, but not necessarily.  
Interestingly, it was reported that three out of 14 and seven out of 10 patients with 
prophythiouracil-induced vasculits had immune complex GN in renal biopsy. 
Bronchoscopic examination and bronchoalveolar lavage (BAL) can be useful in patients with 
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lung involvement. BAL typically shows neutrophilic alveolitis. Haemosiderin-laden 
macrophages may be found in BAL.. 
2.5 Risk for drug-induced vasculitis 
In contrast to primary ANCA associated vasculitis, which occurs more often in the elderly, 
the demographic characteristics of patients with drug-induced vasculitis may reflect the 
features of the underlying diseases. For example, patients with drug-induced vasculits are 
younger and predominantly female, which might merely be a reflection of the greater 
prevalence of thyroid disease in young women. Furthermore, a preponderance of reported 
cases are from countries in Europe and Asia where the medical community, in sharp 
contrast to that in the USA, preferentially manages hyperthyroid states with thionamides 
rather than with radioactive iodine. Long-standing therapy using the offending drug might 
be a risk factor for developing clinically evident vasculitis. In vitro, some studies confirmed 
that in contrast to short-term treatment with the parent drugs, long-term therapy, which 
allowed for more extensive generation of the reactive intermediates, resulted in sensitization 
of T cells to the intermediates. Because the risk of drug-induced lupus was increasing in 
patients receiving a higher cumulative dose of minocycline and hydralazine, similar results 
might exist in drug-induced vasculitis; however, there is no data on the cumulative 
threshold dose of the causal drugs in drug-induced vasculitis. 
2.6 How to make a proper diagnosis 
Because primary ANCA associated vasculitis is associated with high morbidity and 
mortality, as well as potentially life-threatening toxicity from immunosuppressive therapy, 
identification of potentially reversible causes of specific drugs is very important. Failure to 
recognize the offending drug can lead to fatal organ damage. However, the diagnosis of 
drug-induced vasculits is complicated and difficult for several reasons, including: (a) 
physicians often do not recognize the syndrome as drug-induced (inappropriate diagnosis); 
(b) variable and often prolonged duration between the commencement of therapy and initial 
vasculitic symptoms; and (c) failure to evaluate appropriate laboratory and invasive tests. 
The awareness of drug-induced vasculitis by physicians is important in order to make 
prompt diagnosis and treatment and thus achieving favorable outcomes. It is essential that a 
comprehensive drug history should be obtained in patients with vasculitis. Clinicians 
should seek information on drug use for at least 6 months before presentation. The 
evaluation of pertinent laboratory data and prompt histological confirmation of the disease 
may aid in the diagnosis. Biopsies are strongly encouraged to confirm the presence of 
vasculitis3 and to determine the disease severity. Patients with drug-induced vasculitis 
should fulfilled the 1994 Chapel Hill Consensus Conference definition for ANCA associated 
vasculitis. We suggest that drug-induced vasculitis should be defined further by the 
following: (a) the signs and symptoms of vasculitis are temporally related to using the 
offending drug, and regressed with its discontinuation; (b) serum ANCA is positive, 
especially those with multi-antigenicity; and (c) medical conditions that mimic vasculitis are 
excluded, especially infections and malignancies, and other definable types of vasculitis. A 
low percentage of patients treated long term with a drug risk developing hypersensitivity 
reactions, some of which appear as vasculitis. There are laboratory markers that can help 
distinguish drug induced vasculitis from idiopathic autoimmune diseases, and thorough 
knowledge about such serological changes may help to differentiate drug-induced from 
idiopathic syndromes (summarized in Table 2). 
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Drug-induced 
vasculitis 
SLE AAV 
Antihistone abs. Can be seen Rare Absent 
AntidsDNA abs. Absent Common Absent 
ANCA Commona Rare Commonb 
Antiphospholipid abs. Common Common Rare 
Immune complexes Rare Common Absent 
SLE, systemic lupus erythematosus; AAV, anti-neutrophil cytoplasmic antibodies-associated vasculitis.  
a Multispecific. 
b Single ANCA specificity. 
Table 2. Laboratory marker differences between drug-induced vasculitis and idiopathic 
systemic lupus erythematosus and ANCA associated vasculitis 
2.7 Treatment 
There is no standard approach to the treatment of drug induced vasculitis. Because the 
pathogenesis is different between primary and drug-induced vasculitis, the cornerstone of 
treatment for primary ANCA associated vasculitis, including induction therapy and 
maintenance therapy with combined corticosteroid and cyclophosphamide, might not be 
suitable for patients with drug-induced vasculitis. Treatment should be based on 
individualized assessment in patients with drug-induced vasculitis. Because the offending 
drugs are involved in the pathogenesis, cessation of the casual drug immediately after 
diagnosis is essential and might be enough for those with limited to general systemic 
symptoms. In some case reports, organ involvement such as renal and pulmonary vasculitis 
could resolve only after discontinuation of the casual drug. However, in another case report, 
vasculitis worsened in the next 5 months after withdrawal of medication. Furthermore, in 
the published work it was reported that at least seven patients had died of prophythiouracil-
induced vasculitis in spite of intensive immunosuppressive therapy. Therefore, treatment 
for patients with organ involvement should depend on the severity of clinical 
manifestations and histopathological lesions. For patients with severe and active organ 
involvement, intensive immunosuppressive therapy such as corticosteroid and/or 
immunosuppressive agents could improve organ function and prevent progression to 
severe, irreversible disease. As shown in Table 3, prednisone should be administered at 1 
mg/kg per day for the first 4–8 weeks, followed by a gradual tapering within 6–12 months. 
Cyclophosphamide (0.6–1.0 g/ month i.v., or 1–2 mg/kg per day p.o.) or mycophenolate 
mofetil (1.5–2.0 g/day) could be administered for 6–12 months. In addition, patients with 
severe necrotizing crescentic GN and diffuse pulmonary alveolar hemorrhage should 
receive pulse methylprednisolone (7–15 mg/kg per day) for 3 days, and patients with life-
threatening massive pulmonary hemorrhage may respond to plasmapheresis. It is well 
accepted that treatment for patients with primary ANCA associated vasculitis comprised 
both induction and maintenance therapy. However, for patients with drug-induced 
vasculitis, the duration of immunosuppressive therapy is still inconclusive. The duration of 
immunosuppressive therapy in patients with drug-induced vasculitis could be much shorter 
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than that in primary ANCA associated vasculitis and that as long as the offending drug was 
withdrawn, maintenance therapy might not be necessary. Although ANCA detection may 
provide a clue to the diagnosis of drug-induced vasculitis, positive seroconversion alone 
may not be a sufficient reason to discontinue the offending drug, because only a small 
proportion of the patients with positive ANCA will actually develop clinically evident 
vasculitis. Physicians should carefully monitor those with drug-induced ANCA but without 
clinical vasculitis. Resolution of most symptoms has generally occurred within 1–4 weeks 
except for severe organ involvement. Nonspecific symptoms may resolve dramatically only 
after cessation of the casual drug. However complete resolution of vasculitis occurred in 
most of the reported cases, some patients do have persistent laboratory abnormalities 
(elevated serum creatinine, proteinuria) throughout a long-term follow up. As we 
mentioned before, if necrotizing crescentic GN was present, the patients were at high risk of 
developing chronic renal failure. 
 
Management of causal agents  
    Withdrawal  
    Avoid re-challenges  
    Consider avoiding similar drug classes  
Individualized therapy  
    Non-specific symptoms Withdrawal of causal agents alone 
    Organ involvement Corticosteroid and/or 
immunosuppressive drugs 
    Severe organ involvement (e.g. 
necrotizing  glomerulonephritis,  
focal segmental  
necrotizing glomerulonephritis, diffuse  
alveolar hemorrhage) 
Methylprednisolone pulse therapy, 
followed by combined corticosteroid and 
immunosuppressive drugs 
    Massive pulmonary hemorrhage Plasmapheresis 
Special notes for patients with drug-induced 
vasculitis 
 
    A shorter course of immunosuppressive 
therapy 
 
    Long-term maintenance may not be 
necessary 
 
    Monitoring of serum ANCA 
    Surveillance for emergence of a chronic 
underlying vasculitis 
 
AAV, anti-neutrophil cytoplasmic antibodies-associated vasculitis; ANCA, anti-neutrophil cytoplasmic 
antibodies. 
Table 3. Treatment strategy for patients with drug-induced vasculitis 
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3. Conclusion  
The clinician needs to be aware of this risk and quickly stop the offending drug therapy 
if signs of drug-induced vasculitis develop. In conclusion, patients undergoing 
treatments with the drugs able to induce vasculitis should be monitored closely during 
long-term therapy. ANCA is a useful tool to diagnose discontinued immediately after 
diagnosis. Appropriate immunosuppressive therapy should be administered only for 
patients with vital organ involvement in order to prevent progression to severe, 
irreversible disease. The duration of immunosuppressive therapy should be much 
shorter than that of primary ANCA associated vasculitis and long-term maintenance 
therapy might not be necessary. Identification of predisposing factors to drug-induced 
vaculitis may provide insight into the pathogenesis of primary vasculitis. Finally the 
recommendations for clinicians are: 
 Avoid use of the drugs able to induce drug-induces vasculitis in the long term,  
and patients using long-term treatment with these drugs should be monitored  
carefully. 
 Discontinue the offending drug immediately upon diagnosis of drug-induced 
vasculitis. 
 Individualized immunosuppressive therapy should be initiated according to the 
severity of organ involvement. 
 Adequate documentation of the potentially serious drug-induced reaction in patients’ 
medical records is necessary to avoid re-challenge. 
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